Critical Reviews in Therapeutic Drug Carrier Systems

Papers
(The TQCC of Critical Reviews in Therapeutic Drug Carrier Systems is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Microneedle-Mediated Delivery for Targeted Cancer Therapy: A Comprehensive Review21
Polymeric Nanoparticles Revolutionizing Brain Cancer Therapy: A Comprehensive Review of Strategies and Advances14
Recent Advances in Teriparatide Delivery by-virtue-of Novel Drug Delivery Approaches for the Management of Osteoporosis14
Insight on the Rise and Raise of Drug Delivery with Special Emphasis on Five Classes of Therapeutics13
13
12
12
11
Long-Acting Drug Delivery Technologies for Meloxicam as a Pain Medicine11
10
Stimuli-Responsive Wound Management: A Focus on Innovative pH-Driven Healing Systems10
Immunotherapy in Cervical Cancer: An Evolutionary Paradigm in Women's Reproductive Health9
Peptides as Diagnostic, Therapeutic, and Theranostic Tools: Progress and Future Challenges9
Implementation of Quality by Design in the Formulation and Development of Nanocarrier-Based Drug Delivery Systems8
Advanced Technologies of Drug Delivery to the Posterior Eye Segment Targeting Angiogenesis and Ocular Cancer8
Exploring the Therapeutic Potential of Cyclosporine for Ophthalmic Indications by Novel Carrier Systems7
EMERGING ROLE OF RNA AS A THERAPEUTIC AGENT FOR HUMAN DISEASES: CURRENT TRENDS AND FUTURE DIRECTIONS7
Protein Degradation as a Therapeutic Strategy: The Promise and Progress of Targeted Protein Degraders6
Theranostic Approach for the Management of Osteoporosis6
Reverse engineering and advanced characterization techniques for cost-effective and bioequivalent generic formulation development6
6
Current Review on Nanophytomedicines in the Treatment of Oral Cancer: Recent Trends and Treatment Prospects6
Enhancing Microemulsion-Based Therapeutic Drug Delivery: Exploring Surfactants, Co-Surfactants, and Quality-by-Design Strategies within Pseudoternary Phase Diagrams6
0.045592069625854